The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia

Haematologica

Volumn 100, Issue 4, 2015, Pages e147-e151

  Le Garff Tavernier, Magali ^a,b,c   Herbi, Linda ^a,b,d   De Romeuf, Christophe ^d   Azar, Nabih ^c   Roos Weil, Damien ^a,c   Bonnemye, Patrick ^c   Urbain, Rémi ^d   Leblond, Véronique ^a,c   Merle Beral, Hélène ^a,c,e   Vieillard, Vincent ^a,b,f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Laboratoire Français du Fractionnement et des Biotechnologies   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f Assistance publique Hôpitaux de Paris   (France)

Author keywords

ADCC; Natural killer; Ublituximab; Waldenstr m macroglobulinemia

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CD3 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FC RECEPTOR; FLUDARABINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; RITUXIMAB; UBLITUXIMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; CELL CLONE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; K562 CELL LINE; LETTER; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOSIS; MALE; MIDDLE AGED; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; RAJI CELL LINE; T LYMPHOCYTE; VERY ELDERLY; WALDENSTROEM MACROGLOBULINEMIA; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; WALDENSTROM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; RITUXIMAB; WALDENSTROM MACROGLOBULINEMIA;

EID: 84926300097     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118083     Document Type: Letter

References (15)

1. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
2. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301-317.
3. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12(4):239-252.
4. Le Garff-Tavernier M, Beziat V, Decocq J, et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell. 2010;9(4):527-535.
5. Le Garff-Tavernier M, Decocq J, de Romeuf C, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25(1):101-109.
6. Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 2014;28(1):230-233.
7. Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol. 2012;2012:421702.
8. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012;26(9):2019-2026.
9. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010; 116(19):3853-3864.
10. Li J, Sze DM, Brown RD, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analog therapy. Blood. 2010;115(17):3580-3588.
11. Nielsen CM, White MJ, Goodier MR, Riley EM. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Front Immunol. 2013;4:422.
12. Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109(1):323-330.
13. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008;140(6):635-643.
14. Deng C, Effie Amengual J, Schreeder MT, et al. A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients. J Clin Oncol. 2013;31(15):8575.
15. Ghobrial IM. Choice of therapy for patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2013;31(3):291-293.